Tahami Monfared Amir Abbas, Fu Shuai, Hummel Noemi, Qi Luyuan, Chandak Aastha, Zhang Raymond, Zhang Quanwu
Eisai Inc., 200 Metro Blvd, Nutley, NJ, 07110, USA.
Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.
Neurol Ther. 2023 Aug;12(4):1235-1255. doi: 10.1007/s40120-023-00498-1. Epub 2023 May 31.
Clinical Alzheimer's disease (AD) begins with mild cognitive impairment (MCI) and progresses to mild, moderate, or severe dementia, constituting a disease continuum that eventually leads to death. This study aimed to estimate the probabilities of transitions across those disease states.
We developed a mixed-effects multi-state Markov model to estimate the transition probabilities, adjusted for 5 baseline covariates, using the Health and Retirement Study (HRS) database. HRS surveys older adults in the United States bi-annually. Alzheimer states were defined using the modified Telephone Interview of Cognitive Status (TICS-m).
A total of 11,292 AD patients were analyzed. Patients were 70.8 ± 9.0 years old, 54.9% female, and with 12.0 ± 3.3 years of education. Within 1 year from the initial state, the model estimated a higher probability of transition to the next AD state in earlier disease: 12.8% from MCI to mild AD and 5.0% from mild to moderate AD, but < 1% from moderate to severe AD. After 10 years, the probability of transition to the next state was markedly higher for all states, but still higher in earlier disease: 29.8% from MCI to mild AD, 23.5% from mild to moderate AD, and 5.7% from moderate to severe AD. Across all AD states, the probability of transition to death was < 5% after 1 year and > 15% after 10 years. Older age, fewer years of education, unemployment, and nursing home stay were associated with a higher risk of disease progression (p < 0.01).
This analysis shows that the risk of progression is greater in earlier AD states, increases over time, and is higher in patients who are older, with fewer years of education, unemployed, or in a nursing home at baseline. The estimated transition probabilities can provide guidance for future disease management and clinical trial design optimization, and can be used to refine existing cost-effectiveness frameworks.
临床阿尔茨海默病(AD)始于轻度认知障碍(MCI),并进展为轻度、中度或重度痴呆,构成一个最终导致死亡的疾病连续体。本研究旨在估计跨越这些疾病状态的转变概率。
我们使用健康与退休研究(HRS)数据库,开发了一个混合效应多状态马尔可夫模型来估计转变概率,并对5个基线协变量进行了调整。HRS每两年对美国老年人进行一次调查。阿尔茨海默病状态使用改良的电话认知状态访谈(TICS-m)进行定义。
共分析了11292例AD患者。患者年龄为70.8±9.0岁,女性占54.9%,受教育年限为12.0±3.3年。在初始状态后的1年内,模型估计在疾病早期向更高AD状态转变的概率更高:从MCI转变为轻度AD的概率为12.8%,从轻度转变为中度AD的概率为5.0%,但从中度转变为重度AD的概率<1%。10年后,所有状态向更高状态转变的概率显著更高,但在疾病早期仍然更高:从MCI转变为轻度AD的概率为29.8%,从轻度转变为中度AD的概率为23.5%,从中度转变为重度AD的概率为5.7%。在所有AD状态中,1年后转变为死亡的概率<5%,10年后>15%。年龄较大、受教育年限较少、失业和入住养老院与疾病进展风险较高相关(p<0.01)。
该分析表明,AD早期状态下疾病进展的风险更大,且随时间增加,在年龄较大、受教育年限较少、失业或基线时入住养老院的患者中风险更高。估计的转变概率可为未来疾病管理和临床试验设计优化提供指导,并可用于完善现有的成本效益框架。